Chronic Lymphocytic Leukemia
Featured Article
“New treatments that delay disease progression in patients with hematologic cancer could have a significant impact on the economic burden of hematologic malignancies,” researchers wrote.
By preemptively looking for patients with chronic lymphocytic leukemia (CLL) who are most likely to not respond to therapy with Bruton's tyrosine kinase (BTK) inhibitors in the long-term, or who will…
Treatment consisting of CD19-specific chimeric antigen receptor (CAR) T-cell therapy and concurrent ibrutinib demonstrated improved outcomes and fewer severe adverse events in patients with relapsed…